Abstract:DDR1 has been identified as a cancer‐associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues. Clinically approved multi‐kinase inhibitors, such as nilotinib, inhibit DDR1‐mediated tumor growth in xenograft models, suggesting DDR1 might be a potential target for cancer treatments. Here, we employed an antibody‐based strategy with a novel anti‐DDR1 antibody‐drug conjugate (ADC) for colon carcinoma treatment. We developed T4H11‐DM4, an ADC targeting DDR1 which carries the tubulin inhibitor payload DM4. Immunohistochemical analysis of a tissue microarray containing 100 colon cancer specimens revealed that DDR1 was highly expressed in 81% of tumor tissues. Meanwhile, high expression of DDR1 was associated with poor survival in patients. In vitro, T4H11‐DM4 exhibited potent anti‐proliferative activity with half maximal inhibitory concentration (IC50) values in the nanomolar range in a panel of colon cancer cell lines. In vivo, the antitumor efficacy of T4H11‐DM4 was evaluated in three colon cancer cell lines expressing different levels of DDR1. T4H11‐DM4 achieved complete tumor regression at doses of 5 and 10 mg·kg−1 in HT‐29 and HCT116 tumor models. Moreover, a correlation between in vivo efficacy of T4H11‐DM4 and the levels of DDR1 expression on the cell surface was observed. Tumor cell proliferation was caused by the induction of mitotic arrest, indicating that the antitumor effect in vivo was mediated by DM4. In addition, T4H11‐DM4 was efficacious in oxaliplatin‐resistant colon cancer models. In exploratory safety studies, T4H11‐DM4 exhibited no overt toxicities when multi‐doses were administered at 10 mg·kg−1 into BALB/c nude mice or when a single dose up to 50 mg·kg−1 was administered into BALB/c mice. Overall, our findings highlight the potential of DDR1‐targeted ADC and may facilitate the development of a new effective therapeutic strategy for colon cancer.

Discovery of LLC355 as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1

Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader

Discovery and Optimization of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl)-ethynyl)benzamides As Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (ddr1) Inhibitors

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Discovery of Autophagy-tethering Compounds As Potent NLRP3 Degraders for IBD Immunotherapy

Discovery Of 4-Amino-1h-Pyrazolo [3,4-D] Pyrimidin Derivatives As Novel Discoidin Domain Receptor 1 (Ddr1) Inhibitors

Discovery of Pyrazolo[3,4- d ]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation

Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis

Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype

Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.

Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11

Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors

Discoidin Domain Receptor 1 As a Potent Therapeutic Target in Solid Tumors

Mechanisms mediating arylidene-indolinones induced degradation: thoughts on “Discovery of a Drug-like, Natural Product-Inspired, DCAF11 Ligand Chemotype”

Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells

Discovery of Alkenyl Oxindole as a Novel PROTAC Moiety for Targeted Protein Degradation via CRL4 Recruitment

Research progress of DDR1 inhibitors in the treatment of multiple human diseases

Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader

Targeting of DDR1 with Antibody‐drug Conjugates Has Antitumor Effects in a Mouse Model of Colon Carcinoma

Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis

Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins